{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:29:06Z","timestamp":1740130146217,"version":"3.37.3"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"5","funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1093\/jac\/dkv480","type":"journal-article","created":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T20:43:44Z","timestamp":1454618624000},"page":"1270-1278","source":"Crossref","is-referenced-by-count":4,"title":["Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an<i>in vitro<\/i>pharmacokinetic model of infection"],"prefix":"10.1093","volume":"71","author":[{"given":"Karen E.","family":"Bowker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan R.","family":"Noel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Tomaselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alasdair P.","family":"MacGowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,2,3]]},"reference":[{"key":"2016041309203578000_71.5.1270.1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00149-08"},{"key":"2016041309203578000_71.5.1270.2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01787-10"},{"key":"2016041309203578000_71.5.1270.3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00330-12"},{"key":"2016041309203578000_71.5.1270.4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04614-14"},{"key":"2016041309203578000_71.5.1270.5","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq253"},{"key":"2016041309203578000_71.5.1270.6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02531-14"},{"key":"2016041309203578000_71.5.1270.7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03742-14"},{"key":"2016041309203578000_71.5.1270.8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03652-14"},{"key":"2016041309203578000_71.5.1270.9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1376-1383.2006"},{"key":"2016041309203578000_71.5.1270.10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06416-11"},{"key":"2016041309203578000_71.5.1270.11","unstructured":"Forest Pharmaceuticals Inc. Teflaro (Ceftaroline Fosamil) Injection For Intravenous Use. Full Prescribing Information . 2013. http:\/\/www.frx.com\/pi\/Teflaro_pi.pdf ."},{"key":"2016041309203578000_71.5.1270.12","unstructured":"Ge Y , Floren L , Redman R et al . Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco , CA, USA , 2006. Abstract A-1936. American Society for Microbiology, Washington, DC, USA."},{"key":"2016041309203578000_71.5.1270.13","unstructured":"Ge Y , Redman R , Floren L et al . The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy , San Francisco, CA, USA , 2006. Abstract A-1937. American Society for Microbiology, Washington, DC, USA."},{"key":"2016041309203578000_71.5.1270.14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1088-1095.2003"},{"key":"2016041309203578000_71.5.1270.15","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq255"},{"key":"2016041309203578000_71.5.1270.16","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq254"},{"key":"2016041309203578000_71.5.1270.17","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15 . CLSI, Wayne, PA, USA, 2005."},{"key":"2016041309203578000_71.5.1270.18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01153-07"},{"key":"2016041309203578000_71.5.1270.19","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.4.831"},{"key":"2016041309203578000_71.5.1270.20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00118-09"},{"key":"2016041309203578000_71.5.1270.21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00936-10"},{"key":"2016041309203578000_71.5.1270.22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06111-11"},{"key":"2016041309203578000_71.5.1270.23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00933-10"},{"key":"2016041309203578000_71.5.1270.24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01386-12"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/71\/5\/1270\/11281168\/dkv480.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T21:48:06Z","timestamp":1503524886000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkv480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,3]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,4,13]]},"published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1093\/jac\/dkv480"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkv480","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published":{"date-parts":[[2016,2,3]]}}}